CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 159,973	$ 124,482
Short-term investments	496,788	249,964
Contracts receivable	11,102	522
Inventories	8,033	6,121
Investment in Regulus Therapeutics Inc.	52,096	33,622
Other current assets	7,518	8,727
Total current assets	735,510	423,438
Property, plant and equipment, net	86,198	91,084
Licenses, net	4,572	6,579
Patents, net	15,517	18,646
Deposits and other assets	5,359	5,939
Total assets	847,156	545,686
Current liabilities:
Accounts payable	11,009	10,239
Accrued compensation	12,168	7,878
Accrued liabilities	22,092	15,401
Current portion of long-term obligations	4,408	4,879
Current portion of deferred contract revenue	48,135	35,925
Total current liabilities	97,812	74,322
Long-term deferred contract revenue	142,790	66,656
2 3/4 percent convertible senior notes	150,334	143,990
Long-term obligations, less current portion	6,542	7,402
Long-term financing liability for leased facility	71,288	70,550
Total liabilities	468,766	362,920
Stockholders' equity:
Common stock, $0.001 par value; 200,000,000 shares authorized, 116,471,371 and 101,481,134 shares issued and outstanding at December 31, 2013 and 2012, respectively	116	102
Additional paid-in capital	1,324,804	1,077,150
Accumulated other comprehensive income	21,080	12,480
Accumulated deficit	(967,610)	(906,966)
Total stockholders' equity	378,390	182,766
Total liabilities and stockholders' equity	$ 847,156	$ 545,686